What 7 Analyst Ratings Have To Say About Health Catalyst
7 analysts have shared their evaluations of Health Catalyst (NASDAQ:HCAT) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 5 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 4 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $13.14, a high estimate of $16.00, and a low estimate of $10.00. This current average reflects an increase of 1.08% from the previous average price target of $13.00.
Decoding Analyst Ratings: A Detailed Look
A clear picture of Health Catalyst's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Sarah James | Cantor Fitzgerald | Maintains | Overweight | $16.00 | - |
| Sarah James | Cantor Fitzgerald | Maintains | Overweight | $16.00 | - |
| Scott Schoenhaus | Keybanc | Lowers | Overweight | $10.00 | $12.00 |
| Jessica Tassan | Piper Sandler | Lowers | Overweight | $15.00 | $17.00 |
| Elizabeth Anderson | Evercore ISI Group | Lowers | Outperform | $10.00 | $11.00 |
| Richard Close | Canaccord Genuity | Lowers | Buy | $11.00 | $12.00 |
| Jack Wallace | Guggenheim | Announces | Buy | $14.00 | - |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Health Catalyst. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Health Catalyst compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Health Catalyst's stock. This comparison reveals trends in analysts' expectations over time.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Health Catalyst's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Health Catalyst analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Unveiling the Story Behind Health Catalyst
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.
Health Catalyst's Financial Performance
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Health Catalyst's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 8.56% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Health Catalyst's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -40.37% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Health Catalyst's ROE stands out, surpassing industry averages. With an impressive ROE of -8.09%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Health Catalyst's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -4.29%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 0.68, Health Catalyst faces challenges in effectively managing its debt levels, indicating potential financial strain.
How Are Analyst Ratings Determined?
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.